Thu, Aug 21, 2014, 6:11 AM EDT - U.S. Markets open in 3 hrs 19 mins

Recent

% | $
Quotes you view appear here for quick access.

Advanced Cell Technology Inc. Message Board

ipstissueface 14 posts  |  Last Activity: Aug 7, 2014 8:50 PM Member since: Oct 25, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ipstissueface ipstissueface Aug 7, 2014 8:50 PM Flag

    Very likely. Personally I'm not waiting for some talking head to tell me to buy, time to get is is now before it blows!

  • ipstissueface ipstissueface Aug 6, 2014 3:42 PM Flag

    $25 instantly after they release breast/bladder and lung cancer testing products.

  • ipstissueface by ipstissueface Jul 25, 2014 4:17 PM Flag

    Mr. Pedro Lichtinger has been the Chief Executive Officer and President of Asterias Biotherapeutics, Inc. since Mr. Lichtinger served as the Chief Executive Officer and President of Optimer Pharmaceuticals, Inc. from May 2010 to February 2013. Mr. Lichtinger served as an Executive of Pfizer, Inc. from 1995 to 2009 and as the President of Pfizer's Global Primary Care Business Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and Regional President Europe Animal Health from 1995 to 1999, where he oversaw operations in North America, Europe, Korea, and Australia with revenues of $23 billion, 15,000 employees, and more than 60 development projects. He served as the President of European Pharmaceutical Operations and oversaw all pharmaceutical products including primary care, oncology, specialty and generic. He served as President of Pfizer Animal Health Inc., Global Animal Health Business and Regional President Europe Animal Health. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham, last serving as Senior Vice-President Europe Animal Health from 1987 to 1995. Mr. Lichtinger has over 30 years' experience in the animal health industry in the United States, Latin America and Europe. He also served in a variety of management positions within the animal health divisions of Pfizer and Smith Kline Beecham. His positions included: Country Manager of Brazil; International Business Development Director; Vice-President of southern Europe and Senior Vice-President of Europe. He has broad international and cross functional experience. Mr. Lichtinger serves as President at International Federation for Animal Health. He has been a Director of Asterias Biotherapeutics, Inc. since July 18, 2014. He has been a Director of BioTime, Inc. since August 2009 and serves as a Member of Board of Governors at Boys & Girls Clubs of America. He served as a Director at Optimer Pharmaceutical

  • Be there-Be square

  • Reply to

    Bankruptcy

    by aa112233 Jul 17, 2014 2:00 PM
    ipstissueface ipstissueface Jul 17, 2014 8:42 PM Flag

    Another bashing spam from Baltbear....IGRNORED

  • Reply to

    Last leg of classic 'W' on BTX chart

    by btimnextmicrosoft Jul 9, 2014 1:45 PM
    ipstissueface ipstissueface Jul 15, 2014 7:18 PM Flag

    Major announcements on the way!

  • Reply to

    All you need to know

    by drwestclone Jul 10, 2014 4:13 PM
    ipstissueface ipstissueface Jul 11, 2014 1:25 PM Flag

    Good info!

  • Reply to

    Btx under $4 is a steal

    by btimnextmicrosoft Jul 9, 2014 8:18 PM
    ipstissueface ipstissueface Jul 10, 2014 9:01 PM Flag

    Good call BTIM, thanks for correcting this stooge.

  • Reply to

    Last leg of classic 'W' on BTX chart

    by btimnextmicrosoft Jul 9, 2014 1:45 PM
    ipstissueface ipstissueface Jul 9, 2014 6:37 PM Flag

    Can't miss out on this, too much to be announced short term.....cancer diagnostics in EU, AST IPO, partnerships on next gen regen therapeutics, preclinical results on multiple regen products, as well as start of multiple trials.

  • Here are the key players/links to Biotimes LifeMap/Mt. Sini relationship:

    Google:
    Interview with LifeMap Sciences CEO Corey Bridges
    Eric Schadt of Mt. Sinai School of Medicine
    -----------------------------------------------------------------------------------------------------------------------------------
    BioTime commits $5M to spinoff working with Mount Sinai on big data-powered mhealth products:

    In a decidedly vague announcement Tuesday, regenerative medicine company BioTime’s subsidiary LifeMap Sciences said it’s spun off a mobile health company.

    LifeMap Solutions will “make health easier to measure and manage” by integrating data from mobile devices with other data like genetic profiles, lifestyle data and electronic records in a cloud-based system, BioTime said.

    It’s doing that by working with researchers at the Icahn School of Medicine at Mount Sinai. Specifically, Eric Schadt, the founding director of the school’s Institute for Genomics and Mulitscale Biology, will lend his expertise as the company’s scientific adviser. Mount Sinai’s focus will be on developing a software engine, while LifeMap will develop the entire technology platform, BioTime said.

    CEO Corey Bridges told the San Francisco Business Times that Mount Sinai wasn’t investing money but was allowing the startup to use some of its resources at a significant discount. BioTime, however, did put up a $5 million seed round for the company.
    Bridges is the former business development manager at Netflix and ran marketing for James Cameron and Vince Pace’s 3D technology and production company Cameron Pace Group. Co-founder David Warshawsky is also co-founder and CEO of LifeMap Sciences.

    LifeMap Solutions is based in Alameda, California.

  • Reply to

    Vac2 will be partnered

    by futurequestnow Jun 5, 2014 12:57 PM
    ipstissueface ipstissueface Jun 26, 2014 6:27 PM Flag

    Notice the alinement with top hospitals/institutions/Pharma
    Weill Cornell, Mount Sinai Medical Center, Winsar Institute, TEVA, The Stem Cell Center in Spain...

  • ipstissueface ipstissueface Jun 24, 2014 12:55 AM Flag

    This company has so much going on - it's insane. As for their spine trials, they have a two year lead on competitors like NVIV.

  • Reply to

    Dr James Andrews

    by jetpro3 Jun 6, 2014 5:12 PM
    ipstissueface ipstissueface Jun 6, 2014 9:36 PM Flag

    BTX's ip is cutting edge, CE mark in the EU later this year for our ECM device, next step is 6mo to 1 yr clinical trials and BINGO. Also keep in mind Biotime has patents on over 7 different cartilage progenitor types(nose, ear, knee, etc).....can you say..."BEST OF BREED"???

  • Reply to

    ACTC in trouble....BTX to the rescue

    by btimnextmicrosoft Jun 6, 2014 1:01 PM
    ipstissueface ipstissueface Jun 6, 2014 4:33 PM Flag

    Would be acquisition #7:
    1-Cell Targeting for cancer IP(now OrthoCyte)
    2-Glycosan(for ECM)
    3-ESI for gold standard GMP hesc lines
    4-Gene Cards(now LifeMap) for biological databases
    5-Cell Cure for neural and retinal stem IP
    6-Geron for 600 patents including hesc, telomere and cancer vaccine IP

ACTC
0.0714+0.0004(+0.56%)Aug 20 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.